Fresh from a special protocol assessment agreement with the FDA, Cell Therapeutics Inc. has snagged a lucrative licensing deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor, pacritinib. The potential $172 million deal gives Baxter exclusive commercialization rights for all indications for pacritinib outside the U.S. The two companies will jointly commercialize the drug within the U.S.